OR Royalties Inc. (NYSE:OR) Declares Quarterly Dividend of $0.07

OR Royalties Inc. (NYSE:OR) declared a quarterly dividend on Wednesday, August 5th. Stockholders of record on Wednesday, September 30th will be paid a dividend of 0.065 per share by the basic materials company on Thursday, October 15th. This represents a c) annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Wednesday, September 30th.

OR Royalties has increased its dividend by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 1 consecutive years. OR Royalties has a dividend payout ratio of 33.3% indicating that its dividend is sufficiently covered by earnings. Research analysts expect OR Royalties to earn $1.26 per share next year, which means the company should continue to be able to cover its $0.25 annual dividend with an expected future payout ratio of 19.8%.

OR Royalties Stock Performance

Shares of NYSE OR traded down $0.04 during trading hours on Thursday, hitting $32.20. 453,228 shares of the stock were exchanged, compared to its average volume of 1,181,004. The company’s fifty day simple moving average is $31.86 and its two-hundred day simple moving average is $37.35. The company has a market cap of $6.03 billion, a PE ratio of 24.07 and a beta of 0.75. OR Royalties has a 1-year low of $27.54 and a 1-year high of $48.06.

OR Royalties (NYSE:OR) last announced its quarterly earnings data on Wednesday, August 5th. The basic materials company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.31 by $0.01. OR Royalties had a net margin of 78.09% and a return on equity of 15.10%. The business had revenue of $97.82 million during the quarter, compared to the consensus estimate of $97.93 million. As a group, sell-side analysts expect that OR Royalties will post 1.27 EPS for the current fiscal year.

OR Royalties Company Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.